diastolic filling

di·as·to·lic fill·ing

(dī'ă-stol'ik fil'ing)
Time between opening of the mitral valve and tricuspid valve; includes passive rapid ventricular filling and the atrial contribution.
References in periodicals archive ?
The diastolic filling period was shorter in the LVD group as compared to normals and longer in the AR+Normal EF group as compared to AR+Reduced EF possibly reflecting heart rate differences.
Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects.
Among the topics that Marcus and Harry will discuss are LV Diastolic Filling (an integrative assessment of left atrial pressure and left ventricular end diastolic pressure; Proximal Isovelocity Surface Area (how to apply the continuity principle for calculation of orifice areas using the PISA method); Aortic Stenosis, Aortic Regurgitation, Mitral Stenosis and Mitral Regurgitation (how to assess each condition and manage it); and Pacemaker Optimization (using Doppler echocardiography).
Influence of alteration in preload on the pattern of left ventricular diastolic filling as assessed by Doppler echocardiography in humans.
Left ventricular filling time is the diastolic filling period which starts with the beginning of the E wave (mitral flow velocity during early filling) and ends with the end of A wave (mitral flow velocity during atrial contraction).
026 * 32 Pearson correlation test BNP--brain natriuretic peptide, EF--ejection fraction, E/A--/A-ratio of peak early to late diastolic filling velocity, LA--left atrium, LVEDD--left ventricular end-diastolic diameter, LVESD--left ventricular end-systolic diameter, MR--mitral regurgitation, RVBS--right ventricle basal peak systolic flow, N--number of patients, RVMS--right ventricular mid peak systolic flow, SSM--strain mid-septal 'Statistically significant (p<0.
Earlier this year, Alteon announced that treatment with ALT-711 in DHF (the DIAMOND study) demonstrated that patients who received 210 mg of ALT-711 twice a day in an open-label, 16-week trial experienced a statistically significant reduction in left ventricular mass, a marked improvement in left ventricular diastolic filling and a positive effect on patients' quality of life.
Primary endpoints included changes in exercise tolerance and aortic stiffness; effects on left ventricular hypertrophy, diastolic filling and quality of life (QOL) were also assessed.